[
    [
        {
            "time": "2018-03-22",
            "original_text": "AbbVie Stock Falls on Weak Lung Cancer Study Outcome",
            "features": {
                "keywords": [
                    "AbbVie",
                    "lung cancer",
                    "study outcome"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie Stock Falls on Weak Lung Cancer Study Outcome",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-22",
            "original_text": "AbbVie: Biggest Loss in the S&P 500 on March 22",
            "features": {
                "keywords": [
                    "AbbVie",
                    "S&P 500",
                    "loss"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie: Biggest Loss in the S&P 500 on March 22",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-22",
            "original_text": "AbbVie stock slammed after disappointing results for cancer drug acquired in $5.8 billion deal",
            "features": {
                "keywords": [
                    "AbbVie",
                    "cancer drug",
                    "disappointing results",
                    "$5.8 billion deal"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie stock slammed after disappointing results for cancer drug acquired in $5.8 billion deal",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-22",
            "original_text": "Today’s Research Reports on Stocks to Watch: AbbVie and Pfizer",
            "features": {
                "keywords": [
                    "research reports",
                    "AbbVie",
                    "Pfizer"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Today’s Research Reports on Stocks to Watch: AbbVie and Pfizer",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-22",
            "original_text": "AbbVie’s latest trial data was probably worse than it looked",
            "features": {
                "keywords": [
                    "AbbVie",
                    "trial data",
                    "worse"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie’s latest trial data was probably worse than it looked",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-22",
            "original_text": "Is The AbbVie Dip A Buying Opportunity?",
            "features": {
                "keywords": [
                    "AbbVie",
                    "dip",
                    "buying opportunity"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Is The AbbVie Dip A Buying Opportunity?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-22",
            "original_text": "Asian shares slump on fears of trade war between US, China",
            "features": {
                "keywords": [
                    "Asian shares",
                    "trade war",
                    "US",
                    "China"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "global markets"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Asian shares slump on fears of trade war between US, China",
                "Correlation": 3,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-22",
            "original_text": "Is It Game Over for AbbVie's Promising Cancer Drug?",
            "features": {
                "keywords": [
                    "AbbVie",
                    "cancer drug",
                    "promising"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Is It Game Over for AbbVie's Promising Cancer Drug?",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        }
    ]
]